The significance of the achievement lies in what these cells represent. In mammals, development begins when a sperm fertilizes an oocyte, creating a zygote. In humans, that single cell remains transcriptionally silent, meaning its genome is largely switched off, until the major wave of zygotic genome activation, or ZGA, occurs around the eight-cell stage. At that point, and in the morula cells that follow, the embryo’s cells are totipotent: they possess the extraordinary capacity to give rise to an entire individual, including both the embryo proper and the supporting tissues. Capturing that fleeting state in a dish has long been one of the most coveted goals in stem cell science.

The obstacle has always been access. Human embryos are ethically fraught as research material, and the supply of early cleavage-stage embryos available for study is vanishingly small. As a result, scientists’ understanding of human totipotency remains rudimentary compared with their deep knowledge of pluripotency, the more restricted capacity of embryonic stem cells to form any tissue of the body but not a whole organism. The new protocol addresses that bottleneck directly by offering a controllable, transgene-free method to produce cells that mimic the eight-cell stage without using embryos at all.

At the heart of the method is a novel culture medium formulated by the team, containing specific chemical compounds and cytokines that push pluripotent stem cells into the eight-cell embryo-like state. The researchers describe two routes to get there. The first is a stepwise approach that moves cells from a primed pluripotent state into a naive state and then onward to 8CLCs, a journey that takes only five days starting from naive pluripotent stem cells. The second is a direct conversion from primed pluripotent stem cells, which requires roughly seven days. Both routes yield cells that can be isolated and characterized using the techniques laid out in the protocol.

The technical details matter enormously for reproducibility, which is precisely why the team chose to publish in a protocols journal. The paper walks readers through the induction of the cells, their isolation from the surrounding culture, and their characterization at multiple levels. Characterization includes immunofluorescence imaging, the use of a TPRX1-EGFP reporter line that fluoresces when the cells enter the eight-cell-like state, and single-cell RNA sequencing to profile gene expression cell by cell. The published figures document the generation of naive pluripotent stem cells on feeder layers and on extracellular matrix, the stepwise and direct induction of 8CLCs, and transcriptomic analyses that compare the resulting cells with natural human embryo data.

Crucially, the resulting 8CLCs exhibit transcriptional and epigenetic features resembling those of genuine human eight-cell embryo cells. In plain terms, the cells have switched on many of the same genes that flicker to life during zygotic genome activation, and their epigenetic markings, the chemical modifications that control gene activity without altering DNA sequence, have shifted toward the embryonic configuration. The authors note that their 8CLCs share similarities with eight-cell-like cells generated by other methods, but there are differences in the expression levels of certain totipotency genes and transposable elements, ancient viral remnants in the genome that are famously reawakened during early development. Those differences give researchers an opportunity to compare approaches and refine the models further.

The broader scientific context helps explain why this protocol is generating such excitement. Work in mice had already shown that embryonic stem cell potency fluctuates with the activity of endogenous retroviruses, and that factors such as DUX and the Zscan4 family can activate cleavage-stage gene programs and drive cells into a totipotent two-cell-like state. Subsequent studies identified regulators including Dppa2 and Dppa4, NELFA, and retinoic acid signaling as players in the totipotency window, and chemical cocktails were eventually shown to induce totipotent-like stem cells in mouse systems. For humans, parallel efforts produced 8C-like cells that capture the zygotic genome activation program in vitro, and transient expression of DUX4 was shown to induce a blastomere-like expression program. The new protocol consolidates this knowledge into a practical, transgene-free workflow for human cells.

The team behind the work draws on a strong track record. The protocol builds on the group’s earlier primary research paper, published in Nature in 2022, in which they first reported rolling back human pluripotent stem cells to an eight-cell embryo-like stage. The data discussed in the protocol were generated as part of that study, and representative results are provided alongside the methods. The authors expect that an individual with roughly one year of experience working with human pluripotent stem cell culture would be able to carry out the procedure, a deliberately accessible bar that should allow laboratories around the world to adopt the technique without exotic equipment or rare expertise.

The implications stretch across several fields. For basic developmental biology, 8CLCs offer an ethically unburdened and materially abundant model for dissecting the molecular events surrounding zygotic genome activation, one of the most fundamental transitions in human life. For reproductive medicine, a deeper understanding of early embryogenesis could illuminate causes of infertility and early pregnancy loss, which often trace back to failures in these first few days of development. For regenerative medicine, totipotent-like cells represent the theoretical starting point for generating any cell type in the body, and possibly extraembryonic lineages as well, from a standardized laboratory source. The work also connects to a rapidly expanding ecosystem of embryo models, including blastoids and gastruloids derived from stem cells, which together are assembling a laboratory-based picture of human development from fertilization through implantation and early organogenesis.

As with any powerful technology, the advance arrives with responsibilities. The authors have filed patent applications covering the protocols for human 8CLC generation and characterization, reflecting both the scientific and commercial stakes of the method. Researchers and ethicists will continue to debate the appropriate boundaries for embryo models, even ones that cannot and are not intended to develop into organisms. What is clear is that the availability of a reproducible, transgene-free protocol lowers the barrier to entry for studying the earliest chapter of human development, and that the cells it produces, glowing green when they switch on the right genes and transcribing the ancient program of the eight-cell embryo, will become a standard tool in laboratories probing the origins of human life.

Subject of Research: A protocol for generating totipotent eight-cell embryo-like cells from human pluripotent stem cells to model zygotic genome activation

Article Title: Generation of eight-cell embryo-like cells from human pluripotent stem cells

Article References: Mazid, M. A., Li, Y., Zhao, M., Fu, L., Liu, H., Jiang, Y., Jia, W., Lai, J., Li, J., Li, H., Saeed, B. J., Manzoor, A., Luo, Z., Lai, Y., Wu, L., Zou, Y., Ariyachet, C., Ward, C., Liu, C., … Li, W. (2026). Generation of eight-cell embryo-like cells from human pluripotent stem cells. Nature Protocols. https://doi.org/10.1038/s41596-026-01414-1

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01414-1

Keywords: eight-cell embryo-like cells, human pluripotent stem cells, totipotency, zygotic genome activation, stem cell reprogramming, Nature Protocols, early embryogenesis, naive pluripotency, single-cell RNA sequencing, transgene-free induction, embryo models, developmental biology

The genesis of this symposium reflects a shared commitment by these organizations to not only advance fundamental understanding but also to translate that knowledge into clinical and therapeutic breakthroughs. Central to this mission is the cultivation of emerging scientific talent, representing a critical investment in the future of bioscience. Bringing together expertise from diverse subfields, the organizing committee has meticulously curated a program that encourages dynamic dialogue and cross-fertilization of ideas, enriching both developmental biology and stem cell research.

Leadership of the symposium is entrusted to a distinguished panel of early-career scientists, whose diverse institutional affiliations—from the University of Torino in Italy to the Allen Institute in the United States—exemplify the international and interdisciplinary nature of the event. Their collective experience and emerging leadership promise to drive a forward-looking agenda, encompassing both cutting-edge methodologies and conceptual frameworks that underpin the study of embryogenesis, cell differentiation, and tissue regeneration.

The symposium’s thematic architecture is designed around four core domains, each representing a critical frontier in contemporary research. The first domain, Data Analysis Across Scales, addresses the formidable challenges posed by the integration and interpretation of vast, multi-dimensional datasets. Speakers such as Christina Theodoris from the Gladstone Institute and Sadao Ota of the University of Tokyo are set to explore advanced computational frameworks and machine learning models that enable the dissection of complex biological networks from molecular to organismal levels.

Complementing these computational approaches, the second thematic pillar—Model Systems and the Organism—brings into focus the diverse in vivo and in vitro platforms employed for investigating developmental processes. Experts including Aguilera Castrejon from the Howard Hughes Medical Institute and Marta Shahbazi from the MRC Laboratory of Molecular Biology will discuss novel model systems ranging from genetically engineered mouse models to organoids, highlighting their utility in recapitulating human developmental dynamics and disease phenotypes.

Spatial Awareness, the third thematic focus, delves into the emergent field of spatial omics and tissue architecture. Researchers like Can Aztekin from the Max Planck Institute and Lynn Yap from Nanyang Technological University will elucidate state-of-the-art imaging techniques and spatial transcriptomics technologies that unravel cellular heterogeneity and positional information within developing tissues, fostering a more nuanced understanding of morphogenetic patterning and cellular interactions.

The final thematic domain, Cell Fates and Trials, casts light on the intricate mechanisms guiding stem cell lineage commitment and plasticity amid physiological and pathological contexts. Presenters such as Ariel Waisman from FLENI and Crystal Rogers from the University of California, Davis, will dissect signaling pathways, epigenetic regulation, and environmental cues that orchestrate cell fate decisions, with implications for regenerative medicine and cancer biology.

Beyond presenting pioneering research, the symposium serves as a professional crucible to cultivate soft skills crucial for scientific leadership. Workshops and panel discussions will emphasize mentoring, science communication, and ethical considerations, equipping early-career scientists with a holistic toolkit to navigate and shape the competitive research landscape.

The organizing committee envisions this symposium as a blueprint for future collaborative ventures, amplifying the voices of emerging leaders while building bridges across disciplines and continents. This integrative approach is emblematic of a broader movement towards open science and shared knowledge ecosystems, where transparency and collaboration accelerate discovery and societal impact.

The choice of Seattle as the symposium locale is strategic, given its vibrant biotech ecosystem and proximity to leading research institutions. The city’s infrastructure and scientific milieu provide fertile ground for fostering partnerships that extend beyond the symposium itself, catalyzing long-term collaborations and innovation pipelines.

As the field of stem cell and developmental biology accelerates towards uncovering the fundamental principles governing cell fate and tissue organization, the convening of thought leaders and rising stars at this symposium represents a pivotal moment. It underscores the necessity of interdisciplinary, international cooperation in tackling biological complexity and translating insights into transformative medical applications.

The Allen Institute’s involvement, underscored by its commitment to large-scale open science initiatives, ensures that data and discoveries emanating from the symposium will be accessible, reproducible, and poised to inform future research endeavors worldwide. This approach aligns with contemporary scientific paradigms emphasizing the democratization of knowledge.

Parallelly, the ISSCR and SDB’s vast professional networks and commitment to nurturing scientific careers underscore the symposium’s ambition to be not only a platform for research dissemination but also a catalyst for career development in a rapidly evolving scientific arena.

Prospective participants and interested parties are encouraged to monitor forthcoming announcements detailing the full program and speaker line-up, as the event promises to be a seminal convening for the developmental biology and stem cell research communities. This symposium is not just an event but a vital step toward shaping the next generation of scientific discovery.

Subject of Research:
News Publication Date:
Web References:
Image Credits: Allen Institute
Keywords: Stem cell research, Developmental biology, Cell biology, Data analysis, Model systems, Spatial omics, Cell fate

Nicotine, a well-known stimulant found in tobacco, has long been associated with serious health risks, particularly during pregnancy. Maternal smoking has been linked to a variety of prenatal complications and adverse developmental outcomes in offspring. However, the underlying mechanisms through which nicotine exerts its developmental effects have remained poorly understood. This research sheds light on one such mechanism—epigenetic modifications that persist into adulthood.

The research primarily focuses on how prenatal nicotine exposure can instigate epigenetic changes within the Notch signaling genes in the proximal colon of rats. The Notch signaling pathway is a crucial communication system that regulates cell fate decisions during embryonic development. The dysregulation of Notch signaling has been implicated in various health issues, including cancer, metabolic disorders, and developmental abnormalities. By exploring the effects of prenatal nicotine exposure on this pathway, the researchers highlight a potential link between maternal behaviors and the long-term health of offspring.

In their experimental design, the researchers administered nicotine to pregnant rats throughout gestation to simulate maternal smoking. The offspring of these nicotine-exposed rats were then assessed for epigenetic alterations in Notch signaling genes. Epigenetic modifications, such as DNA methylation and histone modification, were analyzed to determine the extent and nature of these changes. These processes are crucial because they can silence or activate genes without altering the underlying DNA sequence, leading to potential long-term consequences for gene expression.

The findings revealed significant alterations in the DNA methylation patterns of Notch genes among the offspring exposed to nicotine. Specifically, key genes involved in the Notch signaling pathway displayed hypermethylation, suggesting that nicotine exposure may lead to reduced expression of these genes. This reduction can have cascading effects on various cellular processes in the proximal colon, indicating a potential mechanism for developmental issues seen in offspring of mothers who smoke during pregnancy.

The study also delves into the role of other signaling pathways and gene expressions that may interact with the Notch signaling pathway in the context of nicotine exposure. For instance, the authors discuss how changes in Notch signaling can affect adjacent pathways that are vital for colon health and overall developmental outcomes. These complex interactions highlight the importance of considering multiple genetic and epigenetic factors when evaluating the impact of external substances like nicotine during pregnancy.

While the study focuses primarily on rodents, the implications of these findings extend to human health. Epidemiological studies have consistently shown that maternal smoking is linked to increased risks of various developmental disorders, including gastrointestinal issues in children. The elucidation of mechanistic pathways, such as those involved in epigenetic alterations, provides a more comprehensive understanding of how such risks manifest, ultimately informing public health initiatives aimed at reducing smoking during pregnancy.

Moreover, the research emphasizes the need for ongoing investigations into the long-term consequences of prenatal exposures. Epigenetic changes may not only affect the immediate offspring but could also impact subsequent generations. This intergenerational transmission of epigenetic modifications raises important questions about the heritability of traits influenced by environmental factors, including lifestyle choices made by parents.

The intricate balance of gene expression regulated by epigenetic factors could represent a potential target for therapeutic interventions. If specific epigenetic alterations can be identified and understood, researchers might explore ways to reverse or mitigate their effects, opening the door for innovative strategies aimed at improving prenatal health and developmental outcomes.

In conclusion, this pioneering study by Dali and colleagues marks a significant advancement in our understanding of how prenatal nicotine exposure can induce lasting epigenetic changes. By shedding light on the role of the Notch signaling pathway and its associated gene expression alterations, the research not only combats existing misconceptions about prenatal exposure to nicotine but also underscores the importance of preventative measures in maternal health. The broader implications of these findings highlight the critical need for continued research into environmental influences on genetic and epigenetic outcomes, paving the way for enhanced public health policies aimed at safeguarding the next generation.

As our understanding of epigenetic mechanisms continues to evolve, it will be essential to remain vigilant about the implications of parental behaviors during pregnancy. The evidence is compelling—making healthier choices during pregnancy could have profound impacts on future generations, enhancing both individual and public health outcomes.

Subject of Research: Prenatal nicotine exposure and its effects on epigenetic alterations in Notch signaling genes.

Article Title: Prenatal nicotine exposure induces epigenetic alterations in the Notch signaling genes in the proximal colon in rats.

Article References:

Dali, O., Heitz-Marchaland, C., Kernanec, PY. et al. Prenatal nicotine exposure induces epigenetic alterations in the Notch signaling genes in the proximal colon in rats.
BMC Genomics 26, 836 (2025). https://doi.org/10.1186/s12864-025-11960-9

Image Credits: AI Generated

DOI:

Keywords: Epigenetics, prenatal nicotine exposure, Notch signaling, gene expression, maternal health.

For decades, scientists have recognized the importance of maternal nutrition during pregnancy in ensuring healthy fetal growth, providing embryos with essential nutrients to build organs, tissues, and functional systems. However, the EMBL team, led by senior author Alexander Aulehla, uncovered an unexpected and profound signaling function embedded within the metabolic machinery of embryonic cells themselves. By studying mouse embryos as they developed segmented structures destined to become spinal vertebrae, they found that metabolism influences the segmentation clock — an internal oscillator controlling the rhythmic formation of body segments.

At the core of their findings is the paradoxical relationship between metabolic rate and developmental tempo. The researchers observed that when metabolic activity accelerates within embryonic cells, the segmentation clock decelerates, effectively slowing the pace at which embryonic segments are formed. This counterintuitive inverse correlation suggests that metabolism’s influence transcends its classical bioenergetic role. Lead author Hidenobu Miyazawa explains that these results imply metabolism serves as a biological signaling hub, fine-tuning developmental timing beyond mere biomass provision.

Delving deeper, the team conducted precise biochemical analyses to dissect which metabolites might serve as key regulators of the segmentation clock’s rhythm. Surprisingly, they identified fructose-1,6-bisphosphate (FBP), a sugar intermediate from the glycolytic pathway, as a pivotal signaling molecule. FBP, traditionally understood as a metabolic intermediate, was shown to exert control over embryonic segmentation through its interaction with the Wnt signaling pathway — a critical regulator of cell fate and patterning during development.

The utilization of synchronization theory proved instrumental in isolating the signaling role of FBP. Much like an internal circadian clock entraining to external light-dark cycles, the segmentation clock can synchronize with periodic external cues. By applying this framework, Miyazawa and colleagues demonstrated that small, targeted pulses of FBP could act as timing signals, modulating the segmentation clock’s oscillation pace independently of metabolic flux. This finding underscores a sophisticated crosstalk between metabolism and molecular developmental pathways.

Crucially, the team’s experiments showed that restoring signaling components downstream of metabolism could reverse the slowed segmentation phenotype without altering the overall metabolic activity. This establishes metabolism not merely as a passive supplier but as an active pacemaker integrating environmental and internal developmental signals. The implications extend beyond embryology, suggesting that cellular metabolism might bridge internal biological timers with external environmental rhythms such as nutrient availability or circadian cycles.

The molecular oscillations governing the segmentation clock were further linked to spatial patterning within the embryo, implying that metabolic modulation can directly influence the morphological outcome of development. This spatial-temporal interaction enriches our understanding of how embryonic tissues achieve their intricate and patterned architectures, ensuring that timing and positioning of developmental events are tightly coordinated.

As the research community digests these findings, questions naturally arise about the broader consequences of metabolism-driven signaling. Could metabolic states govern developmental plasticity in response to fluctuating environmental conditions? Could manipulation of metabolic pathways present therapeutic avenues in congenital malformations involving segmentation defects? These queries pave the way for exciting new research investigating metabolism’s role as a developmental regulator.

The senior author, Alexander Aulehla, highlights the tantalizing prospect that metabolism may act as a core pacemaker, linking internal developmental clocks to external cyclical cues like the circadian rhythm. Since metabolism inherently fluctuates with feeding cycles and light exposure, it serves as a natural conduit between external environment and genetic programs regulating development. EMBL’s findings provide foundational evidence supporting this integrative hypothesis.

This study’s implications ripple beyond fundamental biology, hinting at connections between metabolic health during pregnancy and precise developmental outcomes. It suggests that metabolic dysregulation, as seen in metabolic syndromes or nutritional deficiencies, could disrupt embryonic clock timing, potentially leading to developmental abnormalities. Thus, metabolism’s role in embryogenesis may be far more complex and vital than previously appreciated.

Overall, this research shifts paradigms by positioning metabolic intermediates as signaling modulators, intricately controlling embryonic temporal dynamics rather than solely energizing the process. It invites a reevaluation of how developmental biology and metabolism intersect, inspiring future studies to further unravel the biochemical languages that orchestrate life’s earliest stages.

For those passionate about the frontiers of developmental and metabolic biology, EMBL’s revelation marks a compelling step forward. By identifying glycolytic metabolites as key timekeepers in embryogenesis, the team broadens our understanding of mechanistic integration within cells and lays groundwork for exploring metabolic control in development, evolution, and disease.

Subject of Research: Animal tissue samples
Article Title: A noncanonical role of glycolytic metabolites controlling the timing of mouse embryo segmentation
News Publication Date: 19-Sep-2025
Web References: http://dx.doi.org/10.1126/sciadv.adz9606
Image Credits: Credit: Creative Team/EMBL
Keywords: Developmental biology, Segmentation clock, Glycolytic pathway, Metabolism

Years later, an encounter with Theodore Shedlovsky, a physical chemist and violinist with a unique penchant for recruiting creative minds from the arts to the sciences, became a pivotal moment. Shedlovsky recognized Shapiro’s intrinsic intelligence and encouraged her to take an organic chemistry course, which was only offered at an honors level. Despite lacking prerequisite credentials, her determination and the intervention of the chemistry department chair allowed her enrollment. She aced the honors course, a success that fundamentally altered her life trajectory, steering her firmly toward science.

Shapiro’s scientific contributions transcend traditional boundaries, reshaping biological understanding through her pioneering work in developmental biology and bacterial cell cycle regulation. Notably, she overturned the long-held dogma that bacteria were merely amorphous “bags of enzymes.” By meticulously studying Caulobacter crescentus—a bacterium exhibiting asymmetric cell division—Shapiro revealed how proteins are dynamically compartmentalized and trafficked to specific cellular locations to orchestrate cell division. This insight fundamentally transformed the field’s view of bacterial cellular organization, demonstrating regulated intracellular spatial dynamics previously believed exclusive to eukaryotic cells.

Together with her husband Harley McAdams, an expert in systems engineering, Shapiro co-founded the new discipline of systems biology at Stanford Medicine. Their interdisciplinary collaboration brought engineers and biologists under one roof, drawing analogies between genetic feedback loops and electrical circuits. This approach provided profound mechanistic insights into how complex genetic networks control cell fate decisions and developmental processes, epitomizing a paradigm shift from reductionist biology to integrated system-level understanding.

A hallmark of Shapiro’s career is her formidable ability to translate basic biological discoveries into innovative therapeutic applications. Her collaboration with chemist Steve Benkovic led to the development of boron-containing antimicrobial agents that dramatically reduce toxicity while efficiently targeting pathogens. These boron-based compounds formed the basis of Anacor Inc., a biotech company that revolutionized antifungal and anti-inflammatory treatments, culminating in a blockbuster acquisition by Pfizer for $5.2 billion. Shapiro’s ventures continued with Boragen and 5Metis, advancing agricultural biosecurity by protecting staple crops with novel antifungal technologies.

Beyond the laboratory, Shapiro’s influence extended into the political and public health arenas. She regularly participated in high-profile discussions on global health threats, engaging with luminaries such as George Shultz, Condoleezza Rice, and Bill Gates. Her advocacy on antimicrobial resistance, bioterrorism, and pandemic preparedness positioned her as a trusted advisor across multiple U.S. presidential administrations. In 2019, she addressed the Senate Armed Services Committee to warn of impending pandemic dangers long before the COVID-19 crisis underscored those concerns.

Shapiro’s scientific journey began under the mentorship of Shedlovsky and Jerry Hurwitz, where her doctoral work elucidated the existence of RNA-dependent RNA polymerase in bacterial viruses. This discovery heightened understanding of RNA’s role beyond a transient messenger and laid conceptual groundwork for technologies like mRNA vaccines that would revolutionize medicine decades later. Such prescient work underscores how fundamental biochemistry intertwined with molecular biology serves as a foundation for transformative biotechnology.

Her academic leadership is equally groundbreaking. Shapiro was the first woman to chair departments at three major institutions, including Albert Einstein College of Medicine, Columbia University, and Stanford Medicine. At Albert Einstein, she transitioned the molecular biology department into a center for developmental biology, choosing to study unconventional bacterial models like Caulobacter crescentus with keen focus on cellular asymmetry—a topic that remains central to understanding stem cell biology and organismal development.

Despite operating in male-dominated environments, Shapiro’s brilliance and tenacity broke through entrenched barriers. Early career challenges such as heckling and exclusion only amplified her resolve to demonstrate scientific excellence. As a mentor, she fostered inclusive and empowering lab cultures, helping numerous trainees navigate career obstacles and flourish as independent researchers. Her mentees frequently cite her unique combination of intellectual rigor and personal care as instrumental in their success.

Shapiro’s interdisciplinary team at Stanford epitomized modern biological research, integrating physicists, chemists, engineers, and biologists. This collaborative ethos catalyzed breakthroughs in visualizing cellular processes; notably, Nobel laureate W.E. Moerner’s single-molecule microscopy was leveraged in her lab to definitively track protein movement within bacterial cells. These technological innovations provided compelling proof that bacterial cells possess sophisticated spatial regulation mechanisms, overturning decades of skepticism.

Her commitment to societal impact extended to founding companies, advising policy makers, and participating in exclusive dialogues shaping national security and health policy. Shapiro embodies the ideal of a “citizen scientist,” whose responsibilities transcend academia to include the stewardship of public understanding and the safeguarding of global health frameworks. As antibiotic resistance and viral pandemics loom large as existential threats, her career exemplifies how science must engage with society at large to address these complex crises.

In recognition of her unparalleled contributions, Shapiro is set to receive the prestigious Lasker-Koshland Award for Special Achievement in Medical Science, joining an elite cadre of scientists who have profoundly shaped biomedical research. The award underscores not only her scientific discoveries but also her transformative leadership, mentorship, and dedication to bridging fundamental science with pressing global health challenges.

Now reflecting on a career spanning over six decades, Shapiro emphasizes the importance of confidence and scientific excellence as antidotes to intimidation and exclusion in STEM fields. Her story—from an indifferent arts student to a pioneering scientist and influential thought leader—serves as a beacon of inspiration to future generations navigating the complex landscapes of science and society.

Subject of Research: Developmental biology, bacterial cell cycle regulation, systems biology, antimicrobial drug development, RNA polymerases in bacteriophages.

Article Title: Lucy Shapiro’s Transformative Journey: From Artistic Beginnings to Pioneering Systems Biology and Global Health Advocacy

News Publication Date: [Not provided]

Web References:

• https://profiles.stanford.edu/lucille-shapiro
• https://profiles.stanford.edu/harley-mcadams
• https://profiles.stanford.edu/w-moerner
• http://med.stanford.edu/profiles/Lloyd_Minor/
• https://profiles.stanford.edu/peterkim
• https://profiles.stanford.edu/christine-jacobs-wagner

References: Not explicitly listed in the original content.

Image Credits: No image credits provided.

Keywords: Developmental biology, systems biology, bacterial cell cycle, RNA polymerase, Caulobacter crescentus, antimicrobial drugs, boron-containing compounds, mRNA vaccines, antibiotic resistance, global health, scientific mentorship, female leadership in STEM.

EMBO’s 2025 cohort features 60 newly elected members representing diverse disciplines ranging from RNA biology and epidemiology to molecular medicine and plant sciences, demonstrating the expansive scope of modern life sciences. What distinguishes this year’s selection is the limited representation from Italy; among the two scientists currently leading research in Italian institutions, Laura Cancedda stands prominently. This highlights the increasing visibility of Italian neuroscience within the broader European research ecosystem, amplified by Cancedda’s exemplary work merging molecular techniques with translational applications.

Membership within EMBO goes beyond recognition; it is an active engagement with the future of life sciences. Members play critical roles by influencing EMBO’s strategic direction through council participation, serving on editorial boards of top-tier scientific journals, and reviewing competitive funding applications. These responsibilities ensure that EMBO remains at the forefront of emerging scientific trends and fosters international collaboration. The rigorous nomination and peer-elected process emphasize the organization’s commitment to excellence and diversity across scientific disciplines.

Fiona Watt, EMBO’s Director, emphasized the vitality of new members by stating, “Science thrives on global collaboration, and the annual election of the new EMBO Members brings fresh energy and inspiration to our community.” This reflects EMBO’s vision of uniting researchers who not only have made substantial scientific advances but also aspire to push the boundaries of life sciences through cooperative efforts. Cancedda’s inclusion promises to infuse valuable insights from her neuroscience expertise, particularly her efforts to decode complex neurodevelopmental disorders.

The formal induction of the 2025 EMBO cohort is set to take place at the upcoming EMBO Members’ Meeting in Heidelberg, Germany, a pivotal event fostering dialogue and collaboration among Europe’s science elite. This gathering provides a platform for members to share cutting-edge research findings and catalyze interdisciplinary partnerships. Membership directories, accessible online, catalog the affiliations and research specialties of all EMBO scientists, facilitating global networking opportunities and knowledge exchange.

Laura Cancedda’s journey exemplifies a robust integration of academic rigor and innovative translational research. After earning her degree in Pharmaceutical Chemistry and Technology from the University of Genoa, she pursued a PhD in Neurophysiology at the Scuola Normale Superiore in Pisa. Her postdoctoral work at the University of California, Berkeley, further augmented her expertise, enabling her to bridge molecular neuroscience with clinical relevance. Since returning to Italy, she has led IIT’s Brain Development and Disease unit, focusing on neurodevelopmental anomalies that underlie disorders such as Down syndrome and autism spectrum conditions.

Her research has delivered groundbreaking insights into brain plasticity – the nervous system’s capacity to adapt structurally and functionally in response to experience or injury. Notably, in 2015, Cancedda’s team published pivotal studies in Nature Medicine and Nature Neuroscience demonstrating that bumetanide, a common diuretic, could restore neural plasticity and alleviate cognitive deficits in Down syndrome models. These studies have profound clinical implications, directly influencing therapeutic strategies aimed at improving cognitive function in affected individuals and inspiring a phase II clinical trial to evaluate bumetanide’s efficacy.

Beyond her academic pursuits, Cancedda co-founded IAMA Therapeutics, a biotech start-up devoted to developing neuroscience-based pharmacological interventions, particularly targeting autism spectrum disorders. This entrepreneurial endeavor exemplifies her commitment to translating laboratory discoveries into novel therapies, addressing urgent unmet medical needs and enhancing patient outcomes. Her work underscores an integrative approach, combining molecular neuroscience, pharmacology, and clinical application.

Over the years, Cancedda’s contributions have been recognized by numerous awards, reflecting her standing in the global neuroscience community. In 2025, she received the FIS2 Advanced Investigator Award from the Italian Science Fund, acknowledging her innovative research leadership. Her earlier accolades include the Telethon Career Award in 2016 for her editorial and experimental achievements in Down syndrome and the prestigious ERC Consolidator Grant, which supported her cutting-edge projects investigating brain development and neuroplasticity mechanisms.

Her dedication to advancing neuroscience is further evidenced by her membership in elite networks such as the FENS-KAVLI Network of Excellence, fostering collaboration across Europe’s leading brain researchers. In 2009, she garnered the Young Investigator Award from the Italian Society of Physiology, marking early recognition that presaged her continuing scientific impact. These honors collectively highlight her influence across basic and applied neuroscience domains.

Cancedda’s research meticulously unravels the cellular and molecular pathways governing neurodevelopmental disorders, placing particular emphasis on the interplay between synaptic function and neural circuit formation. Her laboratory employs a range of innovative methodologies, including in vivo imaging, electrophysiology, and molecular profiling, to interrogate how mutations and environmental factors disrupt brain maturation. The goal is to identify actionable molecular targets that can be modulated pharmacologically to restore typical neural function, an endeavor that holds great promise for neurodevelopmental therapeutics.

The election to EMBO is not merely a personal achievement but a testament to the vibrant scientific culture cultivated at IIT and across Italy. Cancedda’s recognition illustrates the increasing role of Italian researchers in pioneering advances that resonate on the European and global stages. By joining EMBO’s ranks, she will contribute to guiding research agendas and mentoring the next generation of scientists, fostering an environment of excellence and innovation critical for addressing complex neurological diseases.

In sum, Laura Cancedda’s election to EMBO exemplifies the convergence of scientific excellence, clinical relevance, and collaborative spirit essential for modern life sciences. Her work, spanning fundamental neuroscience to translational medicine, continues to illuminate the mechanisms of brain development and disorder, putting forward novel avenues for therapeutic intervention. As EMBO welcomes her into its community, the broader neuroscience field can anticipate exciting advancements fueled by her expertise and visionary leadership.

Subject of Research: Brain Development and Neurodevelopmental Disorders, Neural Plasticity, Neuropharmacology, Down Syndrome, Autism Spectrum Disorders

Article Title: Leading Neuroscientist Laura Cancedda Elected to EMBO for Pioneering Brain Development Research

News Publication Date: July 1, 2025

Web References:

• EMBO Membership Directory: https://people.embo.org/
• Italian Institute of Technology: https://iit.it

Image Credits: Credit: IIT – Istituto Italiano di Tecnologia

Keywords: Life sciences, Scientific community, Scientific organizations, Neuroscience, Developmental neuroscience

X chromosome inactivation is a vital process that balances gene expression in female mammals by silencing one of their two X chromosomes. While in most eutherians, such as humans and other placental mammals, this silencing occurs randomly in the early embryo, the mouse serves as a notable exception. In mice, the paternal X chromosome is selectively silenced through an imprinted mechanism during preimplantation, preceding the random XCI that happens later in embryonic development. However, the epigenetic underpinning of this imprinting contrasts sharply with mechanisms observed in other species.

Investigations have demonstrated that imprinted XCI in mice interestingly operates independently of DNA methylation. Instead, it relies on the repressive histone modification H3K27me3 to silence the maternal Xist allele. This epigenetic hallmark guides the selective inactivation process, showcasing a methylation-independent mode of imprinting that has challenged the classical understanding of DNA methylation as a universal imprinting regulator. The subtleties of this mechanism raise profound questions about how marsupials, which diverged early from the eutherian lineage, manage XCI imprinting at an epigenetic level.

In a meticulously designed study focusing on the opossum, a representative marsupial, scientists identified a Differentially Methylated Region (DMR) overlapping the RSX promoter that exhibits distinct methylation patterns in gametes. Specifically, this promoter region is highly methylated in oocytes but remains hypomethylated in sperm. Notably, this pattern persists into female embryos and adult tissues, implying a heritable epigenetic signature that potentially instructs imprinted XCI in marsupials. This finding contrasts with murine models and suggests a DNA methylation-dependent imprinting mechanism in marsupials.

To probe the functional consequences of DNA methylation at the RSX promoter, researchers employed CRISPR-based genome editing to delete the DNA methyltransferases, DNMT1A and DNMT1B, collectively referred to as DNMT1, in male opossum fibroblasts. DNMT1 enzymes are essential for maintaining DNA methylation after replication, thus their ablation offers a powerful tool to dissect methylation-dependent gene regulation. This epigenetic editing led to a widespread reduction in DNA methylation, including hypomethylation at the RSX promoter, confirming the critical role of DNMT1 in sustaining methylation landscapes in these cells.

Remarkably, loss of DNMT1 triggered ectopic expression of the RSX gene, which is normally silent in male opossums due to the single X chromosome and lack of inactivation. Quantitative PCR analysis revealed robust activation of the RSX transcript, accompanied by the formation of distinct RSX RNA clouds within the nuclei of these fibroblasts, visualized through RNA fluorescence in situ hybridization. This reactivation highlights a cause-effect relationship between DNA methylation and repression of RSX, underlining the instructive role of methylation in maintaining normal expression patterns.

Ectopic RSX expression in male cells had further biological consequences, notably the suppression of X-linked gene activity. Transcriptomic analyses showed X chromosome genes were disproportionately downregulated following DNMT1 ablation. Concomitantly, the overall X-to-autosome expression ratio decreased, signaling a shift in dosage balance likely mediated by aberrant RSX function. These findings indicate that RSX RNA, akin to its eutherian counterpart Xist, orchestrates chromosomal silencing and that its epigenetic control via DNA methylation is pivotal to ensuring proper gene dosage.

Beyond the X chromosome, global DNA methylation loss also unleashed widespread transposable element activation, as seen by increased expression levels of multiple families of mobile genetic elements. This surge points to the central role DNA methylation plays in genome stability, repressing potentially deleterious elements that, if mobilized, could disrupt genomic integrity. Such insights emphasize the dual regulatory functions of methylation in epigenetic gene silencing and transposon control.

Further reinforcing the generality of DNA methylation in imprinting regulation, the study examined expression of the autosomal H19 locus, which is imprinted in marsupials but absent in the opossum genome assembly used in prior screens. Upon DNMT1 deletion, H19 expression levels significantly increased, suggesting that DNA methylation acts broadly across different imprinted loci beyond the X chromosome. This expansion of methylation’s role invites reconsideration of imprinted gene control and reveals evolutionary divergence in epigenetic strategies in marsupials versus placental mammals.

Collectively, these elegant experiments illustrate that, unlike the mouse model, marsupials leverage DNA methylation at the RSX promoter to imprint X chromosome inactivation. This methylation imprint is set during gametogenesis and maintained into embryonic development, dictating allele-specific expression patterns. The interplay between methylation marks and expression of long non-coding RNAs such as RSX presents an evolutionary distinct but functionally analogous system to the eutherian Xist-based paradigm.

These findings also have broader implications for understanding mammalian epigenetics and evolutionary biology. By delineating the divergent mechanisms of dosage compensation and imprinting, this research opens avenues for exploring how epigenetic pathways adapt across species. The use of cutting-edge CRISPR genome editing combined with epigenomic profiling sets a new standard for dissecting functional epigenetic regulation in non-traditional model organisms.

As we refine our grasp on the molecular choreography governing early development, the marsupial model provides a compelling window into alternative strategies evolution has crafted. Epigenetic landscapes are not ubiquitously conserved but reflect lineage-specific adaptations, reminding us that mammalian biology is richly diverse and complex. The revelation that DNA methylation orchestrates RSX silencing in marsupials versus H3K27me3-dependent Xist silencing in mice underscores the dynamic interplay of epigenetic modifications across taxa.

In summary, this study shines light on the crucial but divergent roles that DNA methylation plays in regulating X chromosome inactivation and imprinting across mammalian lineages. It challenges longstanding assumptions derived from murine models and enriches our understanding of epigenetic control mechanisms. As epigenetics continues to unravel the complexities of gene regulation, studies like this reaffirm the value of comparative approaches to decode the evolutionary tapestry of life.

Subject of Research: Epigenetic regulation of X chromosome inactivation and imprinting in marsupial and eutherian embryos

Article Title: Divergent DNA methylation dynamics in marsupial and eutherian embryos

Article References:
Leeke, B.J., Varsally, W., Ogushi, S. et al. Divergent DNA methylation dynamics in marsupial and eutherian embryos. Nature (2025). https://doi.org/10.1038/s41586-025-08992-2

Image Credits: AI Generated

Dr. Ren’s research is characterized by its pioneering exploration of the intricate regulatory mechanisms that dictate how genes express themselves. His extensive work has significantly enriched the scientific community’s comprehension of gene expression dynamics, particularly in developmental biology and pathological conditions. The implications of his findings resonate across various domains, including precision medicine, where understanding these regulatory processes is crucial for tailoring individualized treatment strategies for patients.

The announcement of this appointment was met with immense enthusiasm from colleagues and institutional leaders alike. Tom Maniatis, PhD, co-founder of the NYGC, remarked on Dr. Ren’s record of groundbreaking contributions, emphasizing the impact of his research on our understanding of human development and disease. This recognition underscores the scientific community’s acknowledgment of the profound importance of regulatory mechanisms in health and disease, paving the way for innovative therapies and interventions.

Katrina Armstrong, MD, representing Columbia University, echoed similar sentiments, highlighting Dr. Ren’s multidisciplinary background and collaborative ethos as essential components for success. In today’s complex landscape of biomedical research, collaboration across institutions and disciplines is vital. Dr. Ren’s ability to bridge these divides could lead to remarkable breakthroughs in genomic research that benefit both the scientific community and patients.

Dr. Ren’s appointment is further buoyed by new philanthropic commitments from notable foundations. The Simons Foundation International and the Carson Family Charitable Trust have pledged their support to underwrite core functions of the NYGC through 2029, an endorsement that demonstrates confidence in Dr. Ren’s leadership and vision for the institution. This financial backing not only facilitates ongoing and new initiatives but also empowers the organization to attract leading talent and foster innovative research that translates laboratory discoveries into clinical applications.

The importance of financial support in research cannot be understated. It enables the establishment and maintenance of state-of-the-art genomic research infrastructure, which is crucial for fostering an environment conducive to significant scientific discoveries. As Dr. Ren takes the helm at the NYGC, the alignment of his vision with the philanthropic interests of these foundations creates a promising landscape for impactful research endeavors.

Dr. Ren expressed his excitement upon accepting this role, emphasizing that translating genomic research into practical health solutions has been a lifelong ambition. He aims to leverage the NYGC’s robust genomics capabilities and its collective expertise to foster unprecedented levels of collaboration. Such collaboration is essential for addressing the multifaceted challenges inherent in genomic research and its translation to clinical practice.

The academic and professional trajectory of Dr. Ren is remarkable. Holding a PhD in biochemistry and molecular biology from Harvard University, he has forged a path of notable achievements, including founding the Center for Epigenomics during his tenure at the University of California San Diego. His prolific publication record in high-impact journals reflects a career devoted to advancing the field of genomics, wherein he has earned prestigious accolades, including induction as a fellow of the American Association for the Advancement of Science.

The collaborative spirit of Dr. Ren and the institutions involved—ranging from Columbia University to the NYGC’s founding member organizations—signals a robust framework for future breakthroughs in genomic science. As institutions recognize the need for synergistic efforts in addressing the complexities of human health, Dr. Ren’s collaborative approach stands out, resonating across the scientific community striving to transform research into actionable clinical insights that can profoundly impact patient care.

Research on genomic regulation and expression is particularly pertinent in understanding complex diseases, which often arise from multifactorial genetic and environmental interactions. Dr. Ren’s work in this area promises to shed light on the cellular mechanisms underpinning diseases, offering clues that could lead to novel therapeutic strategies aimed at modifying gene expression patterns involved in disease processes.

Looking forward, it is anticipated that Dr. Ren’s leadership will result in significant advancements in the understanding of genomic architecture and its implications for precision medicine, especially as the NYGC continues to harness its technological capabilities. The potential to facilitate discoveries that intersect genetics with clinical applications suggests a transformative era in both research and patient care, directly addressing the pressing health challenges faced globally.

The emphasis on utilizing genomic knowledge to enhance health outcomes aligns with the broader goals of personalized medicine, which seeks to tailor medical interventions based on individual genetic profiles. As Dr. Ren steps into this transformative role at the NYGC, his vision will likely catalyze a new wave of research initiatives focused on ensuring that genomic discoveries translate into tangible benefits for patients located at the intersection of research, healthcare, and innovation.

In conclusion, the appointment of Dr. Bing Ren as scientific director and CEO of the New York Genome Center heralds a new chapter for genomic research in New York City and beyond. His multifaceted expertise, reinforced by consistent support from philanthropic organizations and institutional collaborators, positions the NYGC to lead breakthroughs essential for advancing human health. The insights gained from this research hold the potential to redefine our approaches to diagnostics, treatment, and ultimately, the prevention of diseases through genomic medicine.

Subject of Research: Genomic and Epigenetic Research
Article Title: Dr. Bing Ren Appointed as New CEO of New York Genome Center to Advance Genomic Science
News Publication Date: October 2023
Web References: nygenome.org
References: N/A
Image Credits: N/A

Keywords: Genomics, Epigenetics, Precision Medicine, Gene Regulation, Cancer Research, Neurological Disorders, Scientific Collaboration, Biomedical Research